Zhejiang CFMOTO Power (603129.SH): Cumulatively received a refund of U.S. tariffs and interest amounting to $38.6079 million.

15:43 12/08/2026

Chunfeng Power (603129.SH) announced that on February 2026, the U.S. Supreme Court ruled that the government's imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) exceeded its statutory authority, declaring the related tariff measures null and void from the outset. Tariffs collected from U.S. importers must be fully refunded along with interest. The U.S. Customs and Border Protection (CBP) officially commenced the refund process on April 20, 2026. As of now, the company's wholly-owned subsidiary CFP has cumulatively received a total of $38.6079 million in U.S. tariffs and interest refunds.

Zhejiang CFMOTO Power (603129.SH) announced that on February 2026, the U.S. Supreme Court ruled that the governments imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) exceeded its statutory authority, rendering the related tariff measures void from the outset. Tariffs collected from U.S. importers must be fully refunded with interest. The U.S. Customs and Border Protection (CBP) officially initiated the refund process on April 20, 2026. As of now, the companys wholly-owned subsidiary CFP has received a total of $38.6079 million in refunds of U.S. tariffs and interest.

WG ENV TECH (01845) issues a profit warning, expecting that the mid-term loss attributable to shareholders will expand year-on-year to approximately 12 million to 14 million yuan.

SIRNAOMICS-B (02257) has completed the issuance of a total of 2.4356 million subscription shares, raising approximately HKD 11.3 million.

Shijiazhuang Yiling Pharmaceutical (002603.SZ): The clinical trial application for the innovative chemical drug "LB220-D08 Sustained-release Tablets" has been accepted.

WG ENV TECH (01845) issues a profit warning, expecting that the mid-term loss attributable to shareholders will expand year-on-year to approximately 12 million to 14 million yuan.

SIRNAOMICS-B (02257) has completed the issuance of a total of 2.4356 million subscription shares, raising approximately HKD 11.3 million.

Shijiazhuang Yiling Pharmaceutical (002603.SZ): The clinical trial application for the innovative chemical drug "LB220-D08 Sustained-release Tablets" has been accepted.